Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
Hydroxycarbamide in Relapsing acute myeloid leukemia: NCT07766850 Clinical Landscape Report 2026
9 min read
Hydroxycarbamide in Relapsing acute myeloid leukemia: NCT07766850 Clinical Landscape Report 2026
11 September 2026
NCT07766850 clinical landscape for Relapsing acute myeloid leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white spac…
Read →
Abatacept in Sickle Cell Trait: NCT07616154 Clinical Landscape Report 2026
9 min read
Abatacept in Sickle Cell Trait: NCT07616154 Clinical Landscape Report 2026
11 September 2026
NCT07616154 clinical landscape for Sickle Cell Trait: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
Sitagliptin Phosphate in Parkinson Disease: NCT07804381 Clinical Landscape Report 2026
9 min read
Sitagliptin Phosphate in Parkinson Disease: NCT07804381 Clinical Landscape Report 2026
11 September 2026
NCT07804381 clinical landscape for Parkinson Disease: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
Delandistrogene moxeparvovec in Muscular Dystrophy, Duchenne: NCT07542314 Clinical Landscape Report 2026
9 min read
Delandistrogene moxeparvovec in Muscular Dystrophy, Duchenne: NCT07542314 Clinical Landscape Report 2026
11 September 2026
NCT07542314 clinical landscape for Muscular Dystrophy, Duchenne: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
MWN105 in Diabetes Mellitus, Type 2: NCT07803809 Clinical Landscape Report 2026
9 min read
MWN105 in Diabetes Mellitus, Type 2: NCT07803809 Clinical Landscape Report 2026
11 September 2026
NCT07803809 clinical landscape for Diabetes Mellitus, Type 2: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
Carboplatin in Triple Negative Breast Cancer: NCT07783659 Clinical Landscape Report 2026
9 min read
Carboplatin in Triple Negative Breast Cancer: NCT07783659 Clinical Landscape Report 2026
11 September 2026
NCT07783659 clinical landscape for Triple Negative Breast Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
Mifamurtide in Osteosarcoma: NCT07787429 Clinical Landscape Report 2026
9 min read
Mifamurtide in Osteosarcoma: NCT07787429 Clinical Landscape Report 2026
11 September 2026
NCT07787429 clinical landscape for Osteosarcoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
Mepolizumab in Churg-Strauss Syndrome: NCT07343661 Clinical Landscape Report 2026
9 min read
Mepolizumab in Churg-Strauss Syndrome: NCT07343661 Clinical Landscape Report 2026
11 September 2026
NCT07343661 clinical landscape for Churg-Strauss Syndrome: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
HCXT-2001 in Psoriasis: NCT07792928 Clinical Landscape Report 2026
9 min read
HCXT-2001 in Psoriasis: NCT07792928 Clinical Landscape Report 2026
11 September 2026
NCT07792928 clinical landscape for Psoriasis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
Lenvatinib mesylate in Locally Advanced Clear Cell Renal Cell Carcinoma: NCT07741617 Clinical Landscape Report 2026
9 min read
Lenvatinib mesylate in Locally Advanced Clear Cell Renal Cell Carcinoma: NCT07741617 Clinical Landscape Report 2026
11 September 2026
NCT07741617 clinical landscape for Locally Advanced Clear Cell Renal Cell Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and develo…
Read →
Zoldonrasib in Pancreatic adenocarcinoma metastatic: NCT07805954 Clinical Landscape Report 2026
9 min read
Zoldonrasib in Pancreatic adenocarcinoma metastatic: NCT07805954 Clinical Landscape Report 2026
11 September 2026
NCT07805954 clinical landscape for Pancreatic adenocarcinoma metastatic: endpoints, sponsor, phase, geography, readouts, asset context and development white…
Read →
Risvutatug Rezetecan in Metastatic castration-resistant prostate cancer: NCT07802704 Clinical Landscape Report 2026
9 min read
Risvutatug Rezetecan in Metastatic castration-resistant prostate cancer: NCT07802704 Clinical Landscape Report 2026
11 September 2026
NCT07802704 clinical landscape for Metastatic castration-resistant prostate cancer: endpoints, sponsor, phase, geography, readouts, asset context and develop…
Read →